1. Historic psychedelic drug trials and the treatment of anxiety disorders
- Author
-
Allan H. Young, James Rucker, Luke A Jelen, Catherine Bird, Neil M. Weston, Gemma Knight, Aster Daniel, David Goldsmith, and Damian Gibbs
- Subjects
Combined use ,Psychological therapy ,PsycINFO ,Anxiety ,Psilocybin ,03 medical and health sciences ,0302 clinical medicine ,Surveys and Questionnaires ,medicine ,Humans ,Medical diagnosis ,business.industry ,Psychedelic drug ,Anxiety Disorders ,030227 psychiatry ,Pharmacological action ,Psychiatry and Mental health ,Clinical Psychology ,Pharmaceutical Preparations ,Hallucinogens ,medicine.symptom ,business ,030217 neurology & neurosurgery ,medicine.drug ,Clinical psychology - Abstract
INTRODUCTION In this paper, we systematically review literature from 1940 to 2000 relating to the combined use of psychological therapies and psychedelic drugs in the treatment of ICD-10 anxiety disorders. METHODS The databases Ovid MEDLINE(R), PsycINFO, and Multidisciplinary Association for Psychedelic Studies (MAPS) were searched for case reports and trials involving humans in the treatment of ICD-10 anxiety and related disorders. Twenty-four studies are described; four describe anxiety symptoms in diverse patient groups, 14 studies describe historic diagnoses that usefully correspond with ICD-10 anxiety disorders, six studies pooled results or failed to detail results specific to contemporary ICD-10 anxiety disorders. Two of the 24 studies reported are individual case reports while two of them were inadequate in terms of the reporting of outcome measures. Thus 20 studies were ultimately included in the summary analysis. RESULTS Three of the 20 studies reviewed described improvements in anxiety by standardized measures (p
- Published
- 2020
- Full Text
- View/download PDF